Ciprolet for cystitis

Inflammation of the bladder, as a rule, occurs due to the entry of bacteria into it, so for its treatment, antibacterial drugs are used, including prescribing Ciprolet for cystitis.

Other trade names of this drug, that is, synonyms: Ciprofloxacin, Cipro, Cipriol, Ciprolac, C-flox, Ciprinol, Cifran, Medotsiprin, etc.

Indications Ciproleta for cystitis

Taking into account rather wide spectrum of bactericidal effect of Ciprolet on aerobic Gram-negative and Gram-positive bacteria, indications for its use include infectious (bacterial) inflammations of eyes, ENT and respiratory organs, urogenital system, intestines, abdominal and pelvic organs, bone and joint infectious diseases, as well as bacteremia, bacteriuria and primary sepsis. [1]

Can Ciprolet be used for cystitis? The expediency of using this antibacterial agent is determined by the attending physician - based on the results of microbiological examination (bacteriological examination) of urine, providing the identification of the causative agent. Antimicrobial agents of the group of fluoroquinolones of II generation, which includes the active substance of Ciprolet - ciprofloxacin hydrochloride, are not used for empirical therapy of cystitis, but are used when the effectiveness of other antibiotics is insufficient.

In addition, antibiotic therapy is not indicated for interstitial, drug-induced, radiation-induced bladder inflammation, or cystitis arising from other conditions (diabetes, nephrolithiasis, spinal cord injury).

Read - Antibiotics for cystitis. [2], [3]

Ciprolet for cystitis in women is prescribed under the same conditions, taking into account that in almost 80% of cases of inflammation of the bladder and urinary tract are caused by bacteria from the intestine and lower urinary tract, since the female genital area often contains bacteria that can cause cystitis. The causative bacteria of cystitis are considered by urologists to be Escherichia coli, a bacterium of Escherichia coli, as well as Enterobacter cloacae, Klebsiella spp., Proteus spp., Pseudomonas aeruginosa, and Staphylococcus saprophyticus.

Release form

Ciprolet is available in such forms as tablets (0.25 and 0, 5 g), solution for infusion (in bottles of 100 ml), eye drops (in bottles of 5 ml).

Pharmacodynamics

The active substance of the drug Ciprolet is a synthetic antibiotic of the group of fluoroquinolones of II generation ciprofloxacin (in the form of hydrochloride), which is a bicyclic fluorinated derivative of quinoline carboxylic acid.

The basis of its pharmacological action, leading to the death of pathogens (bactericidal effect), is the ability to specifically irreversibly inhibit topoisomerase enzymes of bacterial cells (DNA topoisomerases II and IV), which ensure replication of their DNA, protein synthesis and reproduction by division.

Pharmacokinetics

After oral administration of Ciprolet ciprofloxacin hydrochloride is rapidly absorbed from the gastrointestinal tract and after one to one and a half hour reaches peak plasma levels. Binding to blood albumin does not exceed 30%, although the average bioavailability is 70%.

Ciprofloxacin hydrochloride penetrates practically into all tissues and biological fluids of the body, crossing the blood-brain barrier; the intrathecal concentration is higher than in blood and remains at a high level for 10-12 hours.

The half-life in plasma lasts 3-5 hours; it is eliminated from the body mainly by the kidneys (in unchanged form), as well as through the intestine.

Dosing and administration

How to take Ciprolet for cystitis? Ciprolet tablets are taken orally before meals, drinking water. A single dose of the drug is one tablet of 0.25 g. During the day, two tablets are taken (with an interval of 12 hours).

How long to take Ciprolet for cystitis? The duration of taking the drug is determined by the doctor - according to the results of urine bacteriological examination. The standard course of treatment is five to seven days.

• Application for children

Due to the threat of impaired development of articular cartilage tissue fluoroquinolone antibacterial agents are contraindicated in children and adolescents under 18 years of age.

Use Ciproleta for cystitis during pregnancy

Antibiotics of the fluoroquinolones group, including Ciprolet and its synonyms containing ciprofloxacin hydrochloride, are not allowed during pregnancy and lactation.

Contraindications

Ciprolet for cystitis is not used if patients have a history of:

• individual hypersensitivity to fluoroquinolones;
• seizure syndrome;
• cerebral circulatory disorders;
• severe renal impairment and/or marked impairment of hepatic enzyme function;
• Hemolytic anemia with glucose-6-phosphate dehydrogenase enzyme deficiency;
• inflammation and dystrophic changes in tendons.

Side effects Ciproleta for cystitis

The use of Ciprolet may cause side effects in the form of:

• nausea, vomiting, abdominal pain, flatulence and diarrhea;
• headaches, dizziness and increased intracranial pressure;
• sleep disturbance, restlessness, generalized depression, tremor; decreased attention, visual and hearing acuity, and impaired taste and smell;
• tachycardia and HR abnormalities;
• skin itching and allergic rashes on the skin, hypersensitivity to ultraviolet radiation;
• decreases in the levels of white blood cells, granulocytes and platelets in the blood;
• weakened and compromised tendons;
• blood, protein, calcium oxalate crystals in the urine;
• urinary disorders involving the renal glomeruli.

Overdose

Ciprolet overdose leads to an increase in its gastrointestinal side effects, as well as to the appearance of seizures and neurotic symptoms. There is no special antidote, individual symptoms are treated.

Interactions with other drugs

The following interactions with other drugs are noted in the instructions for Ciprolet:

• Ciprolet is not taken simultaneously with antacids, Theophylline, Santuril (Probenecid), antituberculosis antibiotic Rifampicin, selective immunosuppressant Cyclosporine, indirect anticoagulant Warfarin;
• concomitant use of fluoroquinolones and blood sugar-lowering drugs, as well as non-steroidal anti-inflammatory drugs (NSAIDs) slows their elimination;
• it is possible to combine Ciprolet with antibiotics of penicillin, aminoglycosides and cephalosporins groups.

Storage conditions

Ciprolet tablets should be stored in a dry place, away from light, at room temperature; solution - at a temperature not lower than +5°C and not higher than +25°C.

Shelf life

The drug is good for use for three years after release.

Analogs of Ciprolet for cystitis

Pharmacotherapeutic effects similar to Ciprolet used in the treatment of bladder inflammation are: antibiotics of the fluoroquinolone group, such as Levofloxacin (Levoflox), Pefloxacin (Peflacin, Pinaflox), Lomefloxacin (Lomflox, Lofox, Okacin); nalidixic acid preparations (Nevigramon, Negram); preparations of pipemidic acid (Palin, Pimidel, Uropimid, Uripipan, Uromidine).

Antimicrobial agents commonly used for bacterial cystitis are Nitrofurantoin (Furadonin), Co-trimoxazole, Fosfomycin (Fosmicin, Uronormin, Monural), and the cephalosporin antibiotics Ceftriaxone and Cephalexin.

Which is better for cystitis, Ciprolet or Nolicin?

Like Ciprolet, Nolicin (synonym Norfloxacin) is an antibiotic of fluoroquinolones group, and has the same mechanism of action and pharmacodynamics. But the bioavailability of norfloxacin, as well as binding to plasma proteins is almost twice lower than that of ciprofloxacin. In addition, the minimum single dose of Nolicin is higher than that of Ciprolet (0.4 g vs. 0.25 g). However, it is possible to take Nolicin for a longer period of time (up to two months) in patients with recurrent chronic cystitis.

Therefore, what is better for cystitis - Ciprolet or Nolicin, for each patient determines the doctor-urologist.

The first FDA statements about the need to limit the use of antibacterial drugs belonging to the fluoroquinolones group due to serious side effects were made in 2016. And in early October 2018, after reviewing all the feedback from patients and doctors regarding the side effects of fluoroquinolone antibiotics, the experts of the European Medicines Agency came to the conclusion that it was necessary to restrict their use.